Display Settings:

Format

Send to:

Choose Destination
    Clin Pharmacol Ther. 2008 Feb;83(2):225-7.

    CYP2D6 phenotype prediction from genotype: which system is the best?

    Source

    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany. julia.kirchheiner@uni-ulm.de

    Abstract

    Genotyping of the polymorphic cytochrome P450 (CYP) 2D6 gene is used increasingly in clinical practice. Several psychiatric hospitals already use CYP2D6 testing before treating a patient with antidepressant or antipsychotic drug therapy. In other fields of drug therapy, such as for breast cancer, CYP2D6 status has been reported to be an independent predictor for the outcome with tamoxifen. Thus, a more favorable tamoxifen treatment seems to be feasible through a priori genetic assessment of CYP2D6.

    PMID:
    18202689
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Nature Publishing Group

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk